BR9608813A - Variante da apolipoprotéina a-i humana ácido nucléico vetor adenovírus célula implante e composição farmacêutica - Google Patents

Variante da apolipoprotéina a-i humana ácido nucléico vetor adenovírus célula implante e composição farmacêutica

Info

Publication number
BR9608813A
BR9608813A BR9608813A BR9608813A BR9608813A BR 9608813 A BR9608813 A BR 9608813A BR 9608813 A BR9608813 A BR 9608813A BR 9608813 A BR9608813 A BR 9608813A BR 9608813 A BR9608813 A BR 9608813A
Authority
BR
Brazil
Prior art keywords
variant
nucleic acid
pharmaceutical composition
acid vector
human apolipoprotein
Prior art date
Application number
BR9608813A
Other languages
English (en)
Inventor
Nicolas Duverger
Gerd Assmann
Patrick Benoit
Eric Bruckert
Jean-Charles Fruchart
Patrice Denefle
Gerald Luc
Gerald Turpin
Harald Funke
Original Assignee
Pasteur Institut
Univ Paris Curie
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Univ Paris Curie, Rhone Poulenc Rorer Sa filed Critical Pasteur Institut
Publication of BR9608813A publication Critical patent/BR9608813A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BR9608813A 1995-05-22 1996-05-20 Variante da apolipoprotéina a-i humana ácido nucléico vetor adenovírus célula implante e composição farmacêutica BR9608813A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9506061A FR2734568B1 (fr) 1995-05-22 1995-05-22 Nouveaux variants de l'apolipoproteine
PCT/FR1996/000747 WO1996037608A1 (fr) 1995-05-22 1996-05-20 Nouveaux variants de l'apolipoproteine a-i

Publications (1)

Publication Number Publication Date
BR9608813A true BR9608813A (pt) 1999-02-17

Family

ID=9479241

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9608813A BR9608813A (pt) 1995-05-22 1996-05-20 Variante da apolipoprotéina a-i humana ácido nucléico vetor adenovírus célula implante e composição farmacêutica

Country Status (16)

Country Link
EP (1) EP0827538A1 (pt)
JP (1) JPH11505712A (pt)
KR (1) KR19990021828A (pt)
AU (1) AU717202B2 (pt)
BR (1) BR9608813A (pt)
CA (1) CA2218759A1 (pt)
CZ (1) CZ291376B6 (pt)
FR (1) FR2734568B1 (pt)
HU (1) HUP9802926A3 (pt)
IL (1) IL118336A0 (pt)
MX (1) MX9708727A (pt)
NO (1) NO975367L (pt)
SK (1) SK156397A3 (pt)
TW (1) TW434260B (pt)
WO (1) WO1996037608A1 (pt)
ZA (1) ZA964097B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) * 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP2004500105A (ja) * 2000-03-13 2004-01-08 アムジエン・インコーポレーテツド Ｔ細胞シグナル伝達のアポリポタンパク質−ａ−１調節
JP4344136B2 (ja) 2000-11-10 2009-10-14 エフ・ホフマン−ラ・ロシュ・リミテッド アポリポタンパク質類似体
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
CA2486127C (en) 2002-05-17 2014-03-11 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
TW201424770A (zh) 2003-02-14 2014-07-01 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
WO2006012632A2 (en) * 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
US8163699B2 (en) 2006-06-01 2012-04-24 Montreal Heart Institute Method for the treatment of valvular disease
US8268796B2 (en) 2008-06-27 2012-09-18 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use thereof
EP2352830B1 (en) * 2008-10-03 2019-01-16 CuRNA, Inc. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1
RU2532222C2 (ru) 2009-02-16 2014-10-27 Серенис Терапьютикс Холдинг С.А, Миметики аполипопротеина а-i
PL2767546T3 (pl) 2011-02-07 2019-04-30 Cerenis Therapeutics Holding Sa Kompleksy lipoproteinowe i ich wytwarzanie oraz ich zastosowania

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
FR2704556B1 (fr) * 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.

Also Published As

Publication number Publication date
CZ291376B6 (cs) 2003-02-12
HUP9802926A3 (en) 2001-08-28
MX9708727A (es) 1997-12-31
FR2734568A1 (fr) 1996-11-29
HUP9802926A2 (hu) 1999-03-29
SK156397A3 (en) 1998-07-08
AU717202B2 (en) 2000-03-23
JPH11505712A (ja) 1999-05-25
WO1996037608A1 (fr) 1996-11-28
CZ367197A3 (cs) 1998-03-18
NO975367D0 (no) 1997-11-21
EP0827538A1 (fr) 1998-03-11
NO975367L (no) 1997-11-21
TW434260B (en) 2001-05-16
AU5904896A (en) 1996-12-11
ZA964097B (en) 1996-12-06
KR19990021828A (ko) 1999-03-25
CA2218759A1 (fr) 1996-11-28
IL118336A0 (en) 1996-09-12
FR2734568B1 (fr) 1997-06-20

Similar Documents

Publication Publication Date Title
BR9608813A (pt) Variante da apolipoprotéina a-i humana ácido nucléico vetor adenovírus célula implante e composição farmacêutica
BR9607317A (pt) Peptídios e composição farmacêutica
BR9607318A (pt) Peptidos e composição farmacêutica
PT1105123E (pt) Composicoes farmaceuticas contendo inibidores da lipase e quitosano
IS4720A (is) Aðferð og lyfjablanda til að stýra styrk lípíða
IL117265A (en) Benzazepine- benzoxazepine- and benzothiazepine-N-acetic acid derivatives their preparation and pharmaceutical compositions containing them
FI972821A0 (fi) Geneettisesti ohjatun solukuoleman geenit ja proteiinit
NO994792D0 (no) Kosmetisk og/eller dermatologisk blanding inneholdende et derivat av metylert silanol og et derivat av hydrolysert planteprotein
FR2740686B1 (fr) Formulation pharmaceutique lyophilisee stable
IL117193A0 (en) Poly-pyrrolecarbox-amidenaphthalenic acid derivatives their preparation and pharmaceutical compositions containing them
IS1947B (is) Setin bensýlamínópíperidín efnasambönd og lyfjablöndur þeirra
MA26714A1 (fr) Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant
AU1307299A (en) Stable pharmaceutical compositions including ascorbic acid and methods of using same
NO984878D0 (no) Fremstilling og anvendelse som medikamenter av 3-alkoksypyridin-2-karboksylsyreamidestere
HU9800147D0 (en) Isoxasol-and crotonoil-amide derivatives and pharmaceutical and diagnostical compositions containing them
IL123927A (en) Propanolamine derivatives processes for their preparation and pharmaceutical composition comprising them
ATE186541T1 (de) Quillajasaponin-zusatz und diesen enthaltende impfstoffformulierung
DE69520475D1 (de) Pharmaceutische Zusammensetzung von biologisch aktiven Peptiden oder Proteinen
DK0776658T3 (da) Kosmetiske og/eller farmaceutiske præparater indeholdende sukkertensider og partielle glycerider af fedtsyrer
IL114534A0 (en) Heterocyclic derivatives of azolones their preparaion and pharmaceutical compositions containing them
NO924528L (no) Derivater av humant gallesalt-stimulert lipase og farmasoeytiske sammensetninger som inneholder disse
HUP0001534A3 (en) Phospholipid derivatives of phosphono-carboxylic acids and pharmaceutical compositions containing them
NO995406L (no) Farmasøytiske sammensetninger av tizoksanid og nitazoksanid
BR9604938A (pt) Vírus recombinante deficiente utilização deste vírus composição farmacêutica e célula de mamífero
NO960826D0 (no) Anvendelse av enzymer fra krill i forstoffer

Legal Events

Date Code Title Description
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: SUGIRO O INDEFERIMENTO (9.2) DO PRESENTE PEDIDO, COM BASE NO ARTIGO 37, E EM COMBINACAO AO DISPOSTO NOS ARTIGOS 13 E 18 (PARAGRAFO III).